Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2017 12:22 ET | Source: Ember Therapeutics

Ember Therapeutics Announces Publication in Circulation of Data Validating Utility of BMP-7 to Regulate Scar Formation in the Heart

NEW YORK, July 17, 2017 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and...
May 01, 2017 18:29 ET | Source: Ember Therapeutics

Ember Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services

NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc., (OTCQB:EMBT) a publicly traded company is pleased to announced that it has retained Maxim Group LLC, a leading investment banking...
October 03, 2016 16:55 ET | Source: Ember Therapeutics

Ember Therapeutics Signs Endorsement Deal with 12 Time Olympic Medalist Ryan Lochte

NEW YORK, Oct. 03, 2016 (GLOBE NEWSWIRE) -- EMBER THERAPEUTICS (OTCQB:EMBT), today announced that Olympic Gold Medalist Ryan Lochte has signed an endorsement agreement with the...
September 12, 2016 14:47 ET | Source: Ember Therapeutics

Ember Therapeutics Acquires Dermasilk™ Brands

NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney...
July 06, 2016 08:00 ET | Source: Ember Therapeutics

Knight and Ember Expand Distribution Partnership

MONTREAL and NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc....
May 31, 2016 13:31 ET | Source: Ember Therapeutics

Ember Therapeutics to Present at Marcum MicroCap Conference

NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and...
March 21, 2016 09:33 ET | Source: Ember Therapeutics

Ember Therapeutics Acquires Migralex™

NEW YORK, March 21, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis,...
March 16, 2016 08:30 ET | Source: Ember Therapeutics

Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta™ from Intercytex

NEW YORK, March 16, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis,...
February 23, 2016 17:02 ET | Source: Ember Therapeutics

Ember Therapeutics, Inc. Announces Ticker Symbol Change to EMBT

NEW YORK, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney...
February 03, 2016 14:33 ET | Source: Ember Therapeutics

Ember Therapeutics Completes Reverse Merger and Begins Trading as a Public Company

NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc., a New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and...